C4 Therapeutics Inc [CCCC] stock is trading at $2.33, up 0.87%. In order to assess the stock’s recent performance, you can check whether its short-term value is rising or falling. The CCCC shares have gain 4.95% over the last week, with a monthly amount drifted -5.67%, and not seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Previously, Barclays started tracking the stock with Overweight rating on September 17, 2025, and set its price target to $8. On September 15, 2025, upgrade upgraded it’s rating to Overweight but maintained its price target of $6 on the stock. Guggenheim started tracking the stock assigning a Buy rating and suggested a price target of $8 on September 04, 2025. Wells Fargo upgraded its rating to an Overweight and raised its price target to $12 on December 19, 2024. Stephens started tracking with a Equal-Weight rating for this stock on November 18, 2024, and assigned it a price target of $4. In a note dated January 29, 2024, JP Morgan upgraded a Neutral rating on this stock but restated the target price of $6.
C4 Therapeutics Inc [CCCC] stock has fluctuated between $1.09 and $4.07 over the past year. Currently, Wall Street analysts expect the stock to reach $7 within the next 12 months. C4 Therapeutics Inc [NASDAQ: CCCC] shares were valued at $2.33 at the most recent close of the market. An investor can expect a potential return of 200.43% based on the average CCCC price forecast.
Analyzing the CCCC fundamentals
C4 Therapeutics Inc [NASDAQ:CCCC] reported sales of 30.11M for the trailing twelve months, which represents a drop of -26.90%. Gross Profit Margin for this corporation currently stands at 0.94% with Operating Profit Margin at -4.31%, Pretax Profit Margin comes in at -3.95%, and Net Profit Margin reading is -3.96%. To continue investigating profitability, this company’s Return on Assets is posted at -0.45, Equity is -0.64 and Total Capital is -0.57. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of0.4.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance.
Ratios To Look Out For
For context, C4 Therapeutics Inc’s Current Ratio is 5.76. In addition, the Quick Ratio stands at 5.76 and the Cash Ratio stands at 1.64. Considering the valuation of this stock, the price to sales ratio is 7.50, the price to book ratio is 1.12.
Transactions by insiders
Recent insider trading involved Boyle Scott N, Chief Business Officer, that happened on Feb 18 ’25 when 669.0 shares were sold. Chief Business Officer, Boyle Scott N completed a deal on Feb 14 ’25 to sell 490.0 shares.
